Could a blood vessel blocker boost esophageal cancer treatment?
NCT ID NCT06281886
First seen Nov 17, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial tests whether adding the drug apatinib to standard chemotherapy and radiation helps people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatinib. The study tracks how long the cancer stays under control and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apatinib (a drug that blocks blood vessel growth to tumors)
What this could lead to
If successful, adding apatinib could improve how long patients live without their cancer growing, offering a new option for hard-to-treat esophageal cancer.
What could go wrong
This is a mid-stage trial with only 170 people, so results may not apply to everyone. Apatinib can cause side effects like high blood pressure or bleeding, and the added benefit over standard therapy is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.